Biosite Inc Sample Contracts

AutoNDA by SimpleDocs
FIRST AMENDMENT TO PURCHASE AGREEMENT AND ESCROW INSTRUCTIONS
Purchase Agreement • March 29th, 2002 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances
and
Rights Agreement • October 28th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances • Delaware
TERMINATION AGREEMENT
Termination Agreement • March 31st, 1998 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances • California
1 EXHIBIT 10.7 SUBLEASE BY AND BETWEEN GENERAL ATOMICS AND BIOSITE DIAGNOSTICS, INC.
Sublease • January 7th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances
SELLER"
Purchase Agreement • March 29th, 2002 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances • California
BACKGROUND
Research and Development Agreement • February 10th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances • California
EXHIBIT 1
Joint Filing Agreement • January 16th, 2002 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances

Waddell & Reed Financial, Inc., Waddell & Reed Financial Services, Inc., Waddell & Reed, Inc. and Waddell & Reed Investment Management Company (the "Filing Persons"), hereby agree to file jointly a Schedule 13G and any amendments thereto relating to the aggregate ownership by each of the Filing Persons of any voting equity security of a class which is registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, as required by Rule 13d-1 and Rule 13d-2 promulgated under the Securities Exchange Act of 1934. Each of the Filing Persons agrees that the information set forth in such Schedule 13G and any amendments thereto with respect to such Filing Person will be true, complete and correct as of the date of such Schedule 13G or such amendment, to the best of such Filing Person's knowledge and belief, after reasonable inquiry. Each of the Filing Persons makes no representations as to the accuracy or adequacy of the information set forth in the Schedule 13G or any ame

NON-COMPETITION, NON-DISCLOSURE AND INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT
Non-Competition, Non-Disclosure and Intellectual Property Assignment Agreement • May 18th, 2007 • Biosite Inc • In vitro & in vivo diagnostic substances • California

This Non-competition, Non-disclosure and Intellectual Property Assignment Agreement (the “Agreement”) entered into as of May 17, 2007, is hereby made by and between INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation (the “Company”) and, BIOSITE INCORPORATED, a Delaware corporation (the “Employer”), on the one hand, and Gunars Valkirs, an individual, who is a resident of and employed in the State of California (“Employee”), on the other hand.

AutoNDA by SimpleDocs
CONFIDENTIALITY AGREEMENT
Confidentiality Agreement • May 2nd, 2007 • Biosite Inc • In vitro & in vivo diagnostic substances • California

THIS CONFIDENTIALITY AGREEMENT (this “Agreement”) is being entered into as of May 11, 2006, between BIOSITE INCORPORATED (“Biosite”), on the one hand, and BECKMAN COULTER, INC. (together with its subsidiaries and affiliates, “Beckman Coulter”), on the other hand.

WITNESSETH
Distribution Agreement • March 29th, 2001 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances • California
NON-COMPETITION, NON-DISCLOSURE AND INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT
Non-Competition, Non-Disclosure and Intellectual Property Assignment Agreement • March 26th, 2007 • Biosite Inc • In vitro & in vivo diagnostic substances • California

This Non-competition, Non-disclosure and Intellectual Property Assignment Agreement (the “Agreement”) entered into as of March 24, 2007, is hereby made by and between BECKMAN COULTER,INC., a Delaware corporation (the “Company”) and, BIOSITE INCORPORATED, a Delaware corporation (the “Employer”), on the one hand, and Gunars Valkirs, an individual, who is a resident of and employed in the State of California (“Employee”), on the other hand.

ARTICLE 1 DEFINITIONS
Development, Supply and Distribution Agreement • February 10th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances • California
For Executive Management/Directors
Nonstatutory Stock Option Agreement • February 26th, 2007 • Biosite Inc • In vitro & in vivo diagnostic substances

NONSTATUTORY STOCK OPTION This option is not intended to be an incentive stock option under section 422 of the Internal Revenue Code (the “Code”).

INDEMNITY AGREEMENT
Indemnification Agreement • January 19th, 2005 • Biosite Inc • In vitro & in vivo diagnostic substances • Delaware

THIS INDEMNITY AGREEMENT, dated as of , 200 , between Biosite Incorporated, a Delaware corporation (the “Corporation”), and (the “Indemnitee”),

AGREEMENT AND PLAN OF MERGER by and among: INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation; INCA ACQUISITION, INC., a Delaware corporation; and BIOSITE INCORPORATED, a Delaware corporation Dated as of May 17, 2007
Merger Agreement • May 18th, 2007 • Biosite Inc • In vitro & in vivo diagnostic substances • Delaware

THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of May 17, 2007, by and among INVERNESS MEDICAL INNOVATIONS, INC., a Delaware corporation (“Parent”); INCA ACQUISITION, INC., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Purchaser”); and BIOSITE INCORPORATED, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

CONFIDENTIALITY AGREEMENT
Confidentiality Agreement • May 29th, 2007 • Biosite Inc • In vitro & in vivo diagnostic substances • California

This Confidentiality Agreement (this “Agreement”) is being entered into as of April 11, 2007, between Biosite Incorporated (“Biosite”), on the one hand, and Inverness Medical Innovations, Inc. (together with its subsidiaries and affiliates, “Inverness”), on the other hand.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!